危重型COVID-19患者的微循环、内皮及炎症反应与脓毒性休克不同:病例对照研究
前瞻性观察性病例对照研究,纳入30例危重型COVID-19患者与33例脓毒性休克患者,采用入射暗场视频显微镜测舌下微循环并系列检测IL-6和Syndecan-1。COVID-19组血管活性药需求和血浆乳酸显著低于脓毒性休克组;微循环流脓毒症组更差(MFI 2.6 vs 2.9,P=0.02;PPV 88% vs 97%,P<0.001);IL-6脓毒性休克组高于COVID-19组(1653 vs 253 pg/mL,P=0.03);两组Syndecan-1无差异。结论提示危重型COVID-19不呈现典型脓毒性休克伴组织低灌注的表现,未见明显舌下微循环障碍、广泛内皮损伤或显著炎症细胞因子释放。
要点
- 危重型COVID-19患者血管活性药需求显著少于脓毒性休克患者,血浆乳酸也更低。
- 舌下微循环脓毒性休克组较COVID-19组更差:MFI 2.6 vs 2.9(P=0.02),PPV 88% vs 97%(P<0.001)。
- IL-6脓毒性休克组高于COVID-19组(1653 vs 253 pg/mL,P=0.03);COVID-19组除ICU入住当天外IL-6未高于健康对照。
- 两组Syndecan-1水平无差异,未见广泛内皮损伤证据。
- 与未分化脓毒性休克相比,危重型COVID-19不呈现典型伴组织低灌注的明显休克状态。
适用人群与场景
- 危重型COVID-19患者(30例)与脓毒性休克患者(33例),均为危重症,研究场景为ICU。
研究设计与关键结果
- 前瞻性观察性病例对照研究:30例危重型COVID-19患者对比33例脓毒性休克患者。
- COVID-19组血管活性药需求显著少于脓毒性休克组,血浆乳酸也显著更低。
- 舌下微循环:脓毒性休克组较COVID-19组更差,MFI 2.6 vs 2.9(P=0.02),PPV 88% vs 97%(P<0.001)。
- IL-6:脓毒性休克组高于COVID-19组(1653 vs 253 pg/mL,P=0.03);COVID-19组除ICU入住当天外IL-6未高于健康对照。
- Syndecan-1水平在两组病理组间无差异。
证据类型、等级与局限
- 证据类型:前瞻性观察性病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与未分化脓毒性休克相比,危重型COVID-19不呈现典型伴组织低灌注的明显休克状态。
- 该组危重型COVID-19患者未见明显舌下微循环障碍、广泛内皮损伤或显著炎症细胞因子释放的证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Critically ill patients with COVID-19 infection frequently exhibit a hyperinflammatory response and develop organ failures; however, the underlying mechanisms are unclear. We investigated the microcirculatory, endothelial, and inflammatory responses in critically ill COVID-19 patients and compared them to a group of patients with septic shock in a prospective observational case control study. Thirty critically ill patients with COVID-19 were compared to 33 patients with septic shock.Measurements of sublingual microcirculatory flow using Incident Dark Field video-microscopy and serial measurements of IL-6 and Syndecan-1 levels were performed. COVID-19 patients had significantly less vasoactive drug requirement and lower plasma lactate than those with septic shock. Microcirculatory flow was significantly worse in septic patients than those with COVID-19 (MFI 2.6 vs 2.9 p 0.02, PPV 88 vs 97% P < 0.001). IL-6 was higher in patients with septic shock than COVID-19 (1653 vs 253 pg/mL, P 0.03). IL-6 levels in COVID 19 patients were not elevated compared to healthy controls except on the day of ICU admission. Syndecan-1 levels were not different between the two pathological groups. Compared to patients with undifferentiated septic shock an overt shock state with tissue hypoperfusion does not appear typical of COVID-19 infection. There was no evidence of significant sublingual microcirculatory impairment, widespread endothelial injury or marked inflammatory cytokine release in this group of critically ill COVID-19 patients.
参考来源
- Hutchings SD, Watchorn J, Trovato F, et al. Microcirculatory, Endothelial, and Inflammatory Responses in Critically Ill Patients With COVID-19 Are Distinct From Those Seen in Septic Shock: A Case Control Study. Shock. 2021. PMID: 33021572. doi:10.1097/SHK.0000000000001672
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。